Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101
27 7월 2021 - 5:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
it will host a webinar to present initial data from the dose
escalation portion of its ongoing Phase 1b trial evaluating
ATRC-101 in select solid tumor types on Thursday, July 29, 2021, at
8:00 a.m. ET.
Conference Call and Webcast Information
The live webcast, including slides, can be accessed through the
Events & Presentations section of the Company's website at
https://ir.atreca.com/news-and-events/event-calendar. To access the
conference call, please dial (800) 373-6606 (United States) or
(409) 937-8918 (international) and reference the conference ID
2386207. An archived replay of the webcast will be available on the
Company's website following the live event.
About ATRC-101
ATRC-101 is a monoclonal antibody derived from an antibody
identified using Atreca’s discovery platform. ATRC-101 is believed
to function through Driver Antigen Engagement, a novel mechanism of
action in oncology. This mechanism involves systemic delivery of an
antibody that, in preclinical models, engages the innate immune
system to cause remodeling of the tumor microenvironment and drive
T cell-mediated destruction of tumor cells. Atreca has identified
the target of ATRC-101 as a tumor-specific ribonucleoprotein (RNP)
complex. ATRC-101 has demonstrated robust anti-tumor activity as a
single agent in multiple preclinical syngeneic tumor models,
including one model in which PD-1 checkpoint inhibitors typically
display limited activity. Further, ATRC-101 has been shown to react
in vitro with a majority of human ovarian, non-small cell lung,
colorectal, breast cancers and acral melanoma samples from multiple
patients. Atreca initiated a Phase 1b first-in-human study of
ATRC-101 in patients with select solid tumor cancers in early 2020.
Clinical trials to evaluate ATRC-101 in combination with a PD-1
inhibitor and in combination with chemotherapy are planned for
2021, as well as in monotherapy dose expansion cohorts in the
ongoing Phase 1b trial.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel
antibody-based immunotherapeutics generated by its differentiated
discovery platform. Atreca's platform allows access to an
unexplored landscape in oncology through the identification of
unique antibody-target pairs generated by the human immune system
during an active immune response against tumors. These antibodies
provide the basis for first-in-class therapeutic candidates, such
as our lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations
and contentions and typically are identified by use of terms such
as "continued," "anticipate," "potential," "expect," "believe,"
"planned," and similar words, although some forward-looking
statements are expressed differently. These statements include
those related to our strategy and future plans, including
statements regarding the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof,
the availability and timing of data from monotherapy dose expansion
cohorts in the Phase 1b trial and from combination cohorts
evaluating ATRC-101 with a PD-1 inhibitor and with chemotherapy.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, clinical
trials, regulatory submissions, and other matters that are
described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024